NCT Number: NCT00002951
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining radiation therapy with chemotherapy may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of chemotherapy plus radiation therapy in treating patients with head and neck cancer.
Looking for future studies?
Notify MeKey information
Conditions
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Louis A. Weiss Memorial Hospital, Chicago, Illinois, United States
About this study
OBJECTIVES:
- Determine the locoregional control rates, time to failure, need for salvage surgery and overall survival of patients with intermediate stage cancer of the oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus.
- Measure the impact of concomitant Hyper-FHX radiotherapy on organ preservation, organ function and quality of life parameters.
- Identify possible prognostic factors for toxic effects and response by performing pharmacologic monitoring.
OUTLINE: Patients receive concomitant chemoradiotherapy with curative intent. Patients who have microscopic or macroscopic residual disease 6 weeks after completion of chemoradiotherapy will receive a surgical salvage procedure.
The first cycle of chemotherapy will begin with PO doses of hydroxyurea every 12 hours on days 0-5. Fluorouracil is given IV on days 0-4. Radiation therapy BID is given on days 1-6. Cycles repeat every 14 days for a total of 5 cycles.
The disease will be reevaluated 4-6 weeks after completion of all treatment, every 3 months for 1 year, then yearly.
PROJECTED ACCRUAL: Approximately 40 patients will be accrued for this study.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
DISEASE CHARACTERISTICS:
- Histologically or cytologically confirmed diagnosis of carcinoma
- Stage II-III (T2, T3, N0 or T1-3, N1) carcinoma of head and neck, including: oral cavity, pharynx, larynx, paranasal sinuses, and cervical esophagus
- No N2 or N3
- Measurable disease is not required
PATIENT CHARACTERISTICS:
Age:
- Not specified
Performance status:
- Zubrod 0-3
Life expectancy:
- Anticipated survival is 3-4 years (median)
Hematopoietic:
- WBC count at least 3.5/mm^3
- Platelet count at least 100,000/mm^3
Hepatic:
- Not specified
Renal:
- Not specified
Cardiovascular:
- Not specified
Pulmonary:
- Not specified
Other:
- No infection or severe medical illness
- Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
- Not specified
Chemotherapy:
- No prior chemotherapy
Endocrine therapy:
- Not specified
Radiotherapy:
- No prior radiotherapy
Surgery:
- No prior surgery
Treatment and study plan
Hydroxyurea
DrugSurgical Procedure
Procedureradiation therapy
RadiationPrimary outcomes
-
Locoregional control rate
Time frame: 8 years
Sponsors and collaborators
Lead sponsor
University of Chicago
Other
Collaborators
- National Cancer Institute (NCI)
Registry information
Official study title
Hyperfractionated Radiotherapy With Concomitant Fluorouracil and Hydroxurea for Intermediate Stage Cancer of the Head and Neck
Important dates
- Study start
- 1996
- Primary completion
- 2004
- Study completion
- 2006
- First posted
- Jan 27, 2003
- Registry last updated
- Sep 5, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Varenicline or Nicotine Patch and Nicotine Gum in Helping Smokers in a Methadone Treatment Program Stop Smoking
NCT00790569
Adenocarcinoma, Bladder Cancer
Providence, Rhode Island, United States
View Trial DetailsHealth Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT00666978
Adenocarcinoma, Bladder Cancer
Kansas City, Kansas, United States
View Trial DetailsZinc Supplements in Lowering Cadmium Levels in Smokers
NCT00376987
Adenocarcinoma, Bladder Cancer
Winston-Salem, North Carolina, United States
View Trial DetailsBupropion in Helping Adults Stop Smoking
NCT00534001
Adenocarcinoma, Bladder Cancer
Buffalo, New York, United States
View Trial Details